ANTI-CD3 Antibodies and Methods of Use
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 62/091,441, filed Dec 12, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,865,251 | ANTI-CD3 Antibodies and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | ||
| US 11,186,650 | ANTI-CD3 Antibodies and Methods of Use In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | ||
| US 10,640,572 | ANTI-CD3 Antibodies and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | ||
| US 11,530,275 | ANTI-CD3 Antibodies and Methods of Use In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | ||
| US 12,466,896 | ANTI-CD3 Antibodies and Methods of Use In force · High confidence | Genentech, Inc | In force | High confidence | ||
| US 11,732,054 | ANTI-CD3 Antibodies and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | ||
| US 10,174,124 | ANTI-CD3 Antibodies and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | ||
| Application 19/337,201 | ANTI-CD3 Antibodies and Methods of Use Abandoned Abandoned Jun 4, 2026 | Genentech, Inc. | Abandoned | Abandoned Jun 4, 2026 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Genentech, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.